We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
General content - Editorial

Direct-to-consumer genetic testing: regulating offer or use?

    Emmanuelle Rial-Sebbag

    UMR U 1027, Inserm, Université de Toulouse, Université Paul Sabatier, Toulouse III, Epidémiologie et analyses en santé publique: risques, maladies chroniques et handicap, Département d’épidémiologie et de santé publique, France

    &
    Pascal Borry

    * Author for correspondence

    Centre for Biomedical Ethics & Law, Katholieke Universiteit Leuven, Kapucijnenvoer 35 Box 7001, 3000 Leuven, Belgium.

    Published Online:https://doi.org/10.2217/pme.12.29
    Free first page

    References

    • Howard HC, Borry P. Is there a doctor in the house?: The presence of physicians in the direct-to-consumer genetic testing context. J. Community Genet.3(2),105–112 (2012).
    • Ledley F. A consumer charter for genomic services. Nat. Biotechnol.20(8),767 (2002).
    • Foster MW, Royal CDM, Sharp RR. The routinisation of genomics and genetics: implications for ethical practices. J. Med. Eth.32(11),635–638 (2006).
    • Howard HC, Borry P. Personal genome testing: do you know what you are buying? Am. J. Bioeth.9(6–7),11–13 (2009).
    • Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am. J. Hum. Genet.82(3),593–599 (2008).
    • Mihaescu R, van HM, Sijbrands EJ et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet. Med.11(8),588–594 (2009).
    • Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet. Med.11(8),570–574 (2009).
    • Wade CH, Wilfond BS. Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests. Am. J. Med. Genet. C. Semin. Med. Genet.142(4),284–292 (2006).
    • Borry P, Howard HC, Senecal K, Avard D. Health-related direct-to-consumer genetic testing: a review of companies’ policies with regard to genetic testing in minors. Fam. Cancer9(1),51–59 (2010).
    • 10  McGuire A, Diaz CM, Wang T, Hilsenbeck S. Social networkers’ attitudes toward direct-to-consumer personal genome testing. Am. J. Bioeth.9(6–7),3–10 (2009).
    • 11  Borry P, van Hellemondt RE, Sprumont D et al. Legislation on direct-to-consumer genetic testing in seven European countries. Eur. J. Hum. Genet. doi:10.1038/ejhg.2011.278 (2012) (Epub ahead of print).
    • 12  Law 94-653 of 29 July 1994 on respect for the human body (1994) (French Law).
    • 13  Law 94-654 of 29 July 1994 on the gift and use of parts and products of the human body, for medical assistance to procreation and prenatal diagnosis (1994) (French Law).
    • 14  Law 2011-814 of 7 July 2011 on Bioethics (2011) (French Law).